about
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.The cellular protein lyric interacts with HIV-1 Gag.VIROTHERAPY RESEARCH IN GERMANY - FROM ENGINEERING TO TRANSLATION A Review as contribution to the Combined Annual Meeting of the German and European Societies of Gene (and Cell) Therapy 2017.A Tupaia paramyxovirus vector system for targeting and transgene expression.Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.Proteome analysis of the HIV-1 Gag interactome.Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors.Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites.Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV VectorsSequencing of serially passaged measles virus affirms its genomic stability and reveals a nonrandom distribution of consensus mutationsMeasles Vaccines Designed for Enhanced CD8+ T Cell ActivationImmunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 AgonistsParamyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex VivoIntroduction to Oncolytic VirotherapyImmunomodulation in Oncolytic Measles VirotherapyMathematical Modeling of Oncolytic Virotherapy
P50
Q35600445-3B4FC045-2A38-49B5-A1EA-584E7971508FQ37035678-B214EA53-2797-4E03-9699-E7563E122031Q38964020-0D9B8B2D-A487-488A-BF0C-B41425FE1BC5Q39669187-368E9FA8-3B17-41F1-8200-CE8BF3DA3901Q40058848-B23B982E-87E2-45AA-8191-49E4B1474FF8Q40082759-1A44CD99-F104-4D64-A07A-3B0F4DAE3C00Q40200208-A8F0D373-6F59-4B74-913B-708074687726Q42206738-AFCEB361-4EDD-476E-AF7A-F007145099C3Q50043857-F12CC63A-2263-4032-85A2-8B485D792E38Q55516215-DC0DE970-005A-470A-9839-CAE7FA874462Q64263017-6946B132-D34F-4A10-AF14-A661BE3152E3Q89693326-2FB18559-6AE3-41AA-939F-E12D837AF913Q89878795-9D6572B9-40DF-46ED-8231-36E0036074D7Q90776241-84C7C6DE-8033-4F07-986E-41BD2F201995Q91137495-7C5F7F07-92A5-46F8-9B9C-057D067B4720Q93113577-91CAD211-4B47-4A56-BDB1-410AD6280F97Q93113610-AE7B794C-5DA4-447F-B234-F63FB0B5D1F2Q93113688-B5874ECA-A85E-4037-9EE1-F1EB5924D86C
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-6032-8786
@en
name
Christine E Engeland
@ast
Christine E Engeland
@en
Christine E Engeland
@es
Christine E Engeland
@nl
type
label
Christine E Engeland
@ast
Christine E Engeland
@en
Christine E Engeland
@es
Christine E Engeland
@nl
prefLabel
Christine E Engeland
@ast
Christine E Engeland
@en
Christine E Engeland
@es
Christine E Engeland
@nl
P214
P106
P21
P214
P31
P496
0000-0001-6032-8786
P735
P7859
viaf-254318738